Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Roivant acquires a Glaxo Alzheimer’s compound

04 Jan 2022

Executive Summary

Roivant Sciences Ltd., via its wholly owned subsidiary Roivant Neurosciences Ltd., acquired GlaxoSmithKline PLC's Phase II SB742457 (GSK742457), a selective 5-HT6 antagonist for cognitive and other functional defects in neurological diseases. NOTES: Roivant Neurosciences is now called Axovant Sciences Ltd. and SB742457 was renamed RVT101.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Product Purchase
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By